NVCR
NovoCure Ltd is a medical systems developer in the United States. Its primary product is the TTFields delivery system, which is a low-intensity therapy to combat acute tumors.
NovoCure Limited (NVCR) is rated C+ (2.7/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B); its weakest is Momentum (C).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-13 | B- (3.0) | C+ (2.5) | B (3.3) | C (2.2) | C+ (2.6) | C+ (2.7) |
| 2026-11-06 | B- (3.0) | C+ (2.5) | B (3.3) | C+ (2.5) | C+ (2.7) | C+ (2.8) |
| 2026-10-30 | B- (3.0) | C+ (2.5) | B (3.4) | C+ (2.8) | C+ (2.7) | B- (2.9) |
| 2026-10-23 | B- (3.0) | C+ (2.5) | B (3.4) | B- (2.9) | C+ (2.6) | B- (2.9) |
| 2026-10-16 | B- (3.0) | C+ (2.5) | B (3.4) | B- (3.0) | C+ (2.6) | B- (2.9) |